|
A phase Ib study of abemaciclib with therapies for metastatic breast cancer. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genentech/Roche |
Consulting or Advisory Role - Lilly (I); MethylGene (I); Symphony Evolution (I); Vaccinex (I) |
Speakers' Bureau - Genentech |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Celgene |
|
|
Consulting or Advisory Role - Novartis; Novartis (I) |
Research Funding - Agensys (Inst); AVEO (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merrimack; Novartis; Pfizer; Syndax |
Research Funding - Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst) |
|
|
Research Funding - Abbvie (Inst); Bayer (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst) |
|
|
Employment - Virginia Oncology Associates |
Research Funding - US Oncology (Inst) |
|
William Jeffery Edenfield |
Speakers' Bureau - Astellas Pharma; Medivation |
|
|
Consulting or Advisory Role - IntegraGen; Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
Consulting or Advisory Role - Celgene (Inst) |
|
|
|
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); Lilly (Inst); OSI Pharmaceuticals (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly (Inst) |
Travel, Accommodations, Expenses - Lilly |